Page 42 - 2018_09-Mondo

A. Kritharis et al.
Clin North Am. 2018;51(1):237-254.
21. Albiñana V, Zafra MP, Colau J, et al. Mutation affecting the proximal promoter of Endoglin as the origin of hereditary hem- orrhagic telangiectasia type 1. BMC Med
Genet. 2017;18(1):20.
22. Cole SG, Begbie ME, Wallace GM, Shovlin
CL. A new locus for hereditary haemorrhag- ic telangiectasia (HHT3) maps to chromo- some 5. J Med Genet. 2005;42(7):577-582.
23. Bayrak-Toydemir P, McDonald J, Akarsu N, et al. A fourth locus for hereditary hemor- rhagic telangiectasia maps to chromosome 7. Am J Med Genet A. 2006;140(20):2155- 2162.
24. Hernandez F, Huether R, Carter L, et al. Mutations in RASA1 and GDF2 identified in patients with clinical features of hereditary hemorrhagic telangiectasia. Hum Genome Var. 2015;2:15040.
1991;48(4):757-763.
37. Marchuk DA. Genetic abnormalities in
hereditary hemorrhagic telangiectasia. Curr
Opin Hematol. 1998;5(5):332-338.
38. Westermann CJ, Rosina AF, de Vries V, Coteau PAd. The prevalence and manifesta- tions of hereditary hemorrhagic telangiecta- sia in the Afro Caribbean population of the Netherlands Antilles: A family screening.
Am J of Med Genet. 2003;116(4):324-328. 39. Williams J-CB, Hamilton JK, Shiller M, Fischer L, Deprisco G, Boland CR. Combined juvenile polyposis and hereditary hemorrhagic telangiectasia. Proc (Bayl Univ
Med Cent). 2012;25(4):360-364.
40. Baert A. Vascular Embolotherapy: A
Comprehensive Approach, Volume 1: General Principles, Chest, Abdomen, and Great Vessels: Springer Science & Business Media, 2006.
41. Donaldson JW, McKeever TM, Hall IP, Hubbard RB, Fogarty AW. Complications and mortality in hereditary hemorrhagic telangiectasia: A population-based study. Neurology. 2015;84(18):1886-1893.
42. Sabba C, Pasculli G, Suppressa P, et al. Life expectancy in patients with hereditary haemorrhagic telangiectasia. QJM. 2006;99(5):327-334.
43. Kjeldsen AD, Vase P, Green A. [Hereditary hemorrhagic telangiectasia. A population- based study on prevalence and mortality among Danish HHT patients]. Ugeskr Laeger. 2000;162(25):3597-3601.
44. Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemor- rhagic telangiectasia (Rendu Osler Weber syndrome). Am J Med Genet. 2000;91(1):66- 67.
45. Garg N, Khunger M, Gupta A, Kumar N. Optimal management of hereditary hemor- rhagic telangiectasia. J Blood Med. 2014;5:191-206.
46. Brydon HL, Akinwunmi J, Selway R, Ul- Haq I. Brain abscesses associated with pul- monary arteriovenous malformations. Br J Neurosurg. 1999;13(3):265-269.
47. ChoD,KimS,KimM,etal.Twocasesof high output heart failure caused by heredi- tary hemorrhagic telangiectasia. Korean Circ J. 2012;42(12):861-865.
48. Dupuis-Girod S, Ginon I, Saurin J-C, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA. 2012;307(9):948-955.
49. OS AA, Friedman CM, White RI Jr. The nat- ural history of epistaxis in hereditary hemor- rhagic telangiectasia. Laryngoscope. 1991;101(9):977-980.
50. Jessurun G, Kamphuis D, Van der Zande F, Nossent J. Cerebral arteriovenous malfor- mations in the Netherlands Antilles: high prevalence of hereditary hemorrhagic telangiectasia-related single and multiple cerebral arteriovenous malformations. Clin Neurol Neurosurg. 1993;95(3):193-198.
51. Morgan T, McDonald J, Anderson C, et al. Intracranial hemorrhage in infants and chil- dren with hereditary hemorrhagic telangiec- tasia (Osler-Weber-Rendu syndrome). Pediatrics. 2002;109(1):E12.
52. Press OW, Ramsey PG. Central nervous sys- tem infections associated with hereditary hemorrhagic telangiectasia. Am J Med. 1984;77(1):86-92.
53. Dong SL, Reynolds SF, Steiner IP. Brain abscess in patients with hereditary hemor- rhagic telangiectasia: case report and litera- ture review. J Emerg Med. 2001;20(3):247- 251.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
Gallione CJ, Repetto GM, Legius E, et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet. 2004;363(9412):852-859. Jelsig AM, Torring PM, Kjeldsen AD, et al. JP-HHT phenotype in Danish patients with SMAD4 mutations. Clin Genet. 2016;90 (1):55-62.
Pierucci P, Lenato GM, Suppressa P, et al. A long diagnostic delay in patients with hered- itary haemorrhagic telangiectasia: a ques- tionnaire-based retrospective study. Orphanet J Rare Dis. 2012;7(1):33.
Harvey RJ, Kanagalingam J, Lund VJ. The impact of septodermoplasty and potassium- titanyl-phosphate (KTP) laser therapy in the treatment of hereditary hemorrhagic telang- iectasia-related epistaxis. Am J Rhinol. 2008;22(2):182-187.
Reh DD, Yin LX, Laaeq K, Merlo CA. A new endoscopic staging system for hereditary hemorrhagic telangiectasia. Int Forum Allergy Rhinol; 2014: Wiley Online Library; 2014. p. 635-639.
Kwaan HC, Silverman S. Fibrinolytic activi- ty in lesions of hereditary hemorrhagic telangiectasia. Arch Dermatol. 1973;107(4): 571-573.
Watanabe M, Hanawa S, Morishima T. Fibrinolytic activity in cutaneous lesions of hereditary hemorrhagic telangiectasia. Jpn J Dermatol B. 1985;95(1):11.
Zaffar N, Ravichakaravarthy T, Faughnan ME, Shehata N. The use of anti-fibrinolytic agents in patients with HHT: a retrospec- tive survey. Ann Hematol. 2015;94(1):145- 152.
Geisthoff UW, Seyfert UT, Kubler M, Bieg B, Plinkert PK, Konig J. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind place- bo-controlled cross-over phase IIIB study. Thromb Res. 2014;134(3):565-571. Fernandez-L A, Garrido-Martin EM, Sanz- Rodriguez F, et al. Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): Regulation ofALK- 1/endoglin pathway in endothelial cells. Thromb Haemost. 2007;97(2):254-262.
de Gussem EM, Snijder RJ, Disch FJ, Zanen P, Westermann CJ, Mager JJ. The effect of N- acetylcysteine on epistaxis and quality of life in patients with HHT: a pilot study. Rhinology. 2009;47(1):85-88.
Longacre AV, Gross CP, Gallitelli M, Henderson KJ, White Jr RI, Proctor DD. Diagnosis and management of gastrointesti- nal bleeding in patients with hereditary hemorrhagic telangiectasia. Am J Gastroenterol. 2003;98(1):59-65.
Nardone G, Rocco A, Balzano T, Budillon G. The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract. Aliment Pharmacol Ther. 1999;13(11):1429-1436.
Livesey JA, Manning RA, Meek JH, et al. Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiecta- sia. Thorax. 2012;67(4):328-333.
Peng HL, Yi YF, Zhou SK, Xie SS, Zhang GS. Thalidomide Effects in Patients with Hereditary Hemorrhagic Telangiectasia During Therapeutic Treatment and in Fli- EGFP Transgenic Zebrafish Model. Chin Med J (Engl). 2015;128(22):3050-3054. Bauditz J, Schachschal G, Wedel S, Lochs H. Thalidomide for treatment of severe
25. Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev. 2010;24(6):203- 219.
26. Goumans M-J, Liu Z, Ten Dijke P. TGF-β sig- naling in vascular biology and dysfunction. Cell Res. 2009;19(1):116-127.
27. Fernández-L A, Sanz-Rodriguez F, Blanco FJ, Bernabéu C, Botella LM. Hereditary hemor- rhagic telangiectasia, a vascular dysplasia affecting the TGF- signaling pathway. Clin Med Res. 2006;4(1):66-78.
28. Pomeraniec L, Hector-Greene M, Ehrlich M, Blobe GC, Henis YI. Regulation of TGF- receptor hetero-oligomerization and signal- ing by endoglin. Mol Biol Cell. 2015;26(17):3117-3127.
29. Scharpfenecker M, van Dinther M, Liu Z, et al. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci. 2007;120(6):964-972.
30. Cunha SI, Magnusson PU, Dejana E, Lampugnani MG. Deregulated TGF- beta/BMP Signaling in Vascular Malformations. Circ Res. 2017;121(8):981- 999.
31. Tual-Chalot S, Oh P, Arthur HM. Mouse Models of Hereditary Haemorrhagic Telangiectasia: Recent Advances and Future Challenges. Front Genet. 2015;6:25.
32. Garrido-Martín EM, Blanco FJ, Roquè M, et al. Vascular Injury Triggers Krüppel-Like Factor 6 (KLF6) Mobilization and Cooperation with Sp1 to Promote Endothelial Activation through Upregulation of the Activin Receptor-Like Kinase 1 (ALK1) Gene. Circ Res. 2012;112(1):113-127.
33. Cirulli A, Liso A, D’Ovidio F, et al. Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemor- rhagic telangiectasia. Acta Haematol. 2003;110(1):29-32.
34. Shao ES, Lin L, Yao Y, Bostrom KI. Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. Blood. 2009;114(10):2197- 2206.
35. Han C, Choe S-w, Kim YH, et al. VEGF neu- tralization can prevent and normalize arteri- ovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2. Angiogenesis. 2014;17(4):823-830.
36. Iannuzzi MC, Hidaka N, Boehnke M, et al. Analysis of the relationship of von Willebrand disease (vWD) and hereditary hemorrhagic telangiectasia and identifica- tion of a potential type IIA vWD mutation (IIe865 to Thr). Am J Hum Genet.
1442
haematologica | 2018; 103(9)